1009828-65-2

Upstream product

• 24806-06-2 4-chloro-but-2-enoyl chloride 
• 51544-74-2 4-bromocrotonic acid chloride 
• 1186029-44-6 2-[2-(2-2-[6-amino-4-(4,5-dichloro-2-fluoro-phenylamino)-quinazolin-7-yloxy]-ethoxy-ethoxy)-ethoxy]-ethanol 

Downstream Products

• 1186029-57-1 methanesulfonic acid 2-[2-(2-2-[6-(4-bromo-but-2-enoylamino)-4-(4,5-dichloro-2-fluoro-phenylamino)-quinazolin-7-yloxy]-ethoxy-ethoxy)-ethoxy]-ethyl ester 
• 1186029-50-4 methanesulfonic acid 2-[2-(2-2-[6-(4-chloro-but-2-enoylamino)-4-(4,5-dichloro-2-fluoro-phenylamino)-quinazolin-7-yloxy]-ethoxy-ethoxy)-ethoxy]-ethyl ester 
• 1009828-68-5 4-dimethylamino-but-2-enoic acid[4-(4,5-dichloro-2-fluoro-phenylamino)-7-(2-2-[2-(2-hydroxy-ethoxy)-ethoxy]-ethoxy-ethoxy)-quinazolin-6-yl]-amide 
• 1186029-45-7 4-methylamino-but-2-enoic acid[4-(4,5-dichloro-2-fluoro-phenylamino)-7-(2-2-[2-(2-hydroxy-ethoxy)-ethoxy]-ethoxy-ethoxy)-quinazolin-6-yl]-amide 

Relevant academic research and scientific papers

Modified PEG-anilinoquinazoline derivatives as potential EGFR PET agents

Inhibition of epidermal growth factor receptor tyrosine kinase (EGFR-TK) has emerged as a major approach for cancer-targeted therapy. Consequently, there has been a great interest in the use of labeled EGFR-TK inhibitors as positron emission tomography (P